0001209191-20-018258.txt : 20200311
0001209191-20-018258.hdr.sgml : 20200311
20200311190719
ACCESSION NUMBER: 0001209191-20-018258
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200309
FILED AS OF DATE: 20200311
DATE AS OF CHANGE: 20200311
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kauffman Michael
CENTRAL INDEX KEY: 0001364719
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36167
FILM NUMBER: 20706744
MAIL ADDRESS:
STREET 1: C/O KARYOPHARM THERAPEUTICS INC.
STREET 2: 85 WELLS AVENUE, SECOND FLOOR
CITY: NEWTON
STATE: MA
ZIP: 02459
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc.
CENTRAL INDEX KEY: 0001503802
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 263931704
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 85 WELLS AVENUE
STREET 2: SECOND FLOOR
CITY: NEWTON
STATE: MA
ZIP: 02459
BUSINESS PHONE: 617-658-0600
MAIL ADDRESS:
STREET 1: 85 WELLS AVENUE
STREET 2: SECOND FLOOR
CITY: NEWTON
STATE: MA
ZIP: 02459
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-03-09
0
0001503802
Karyopharm Therapeutics Inc.
KPTI
0001364719
Kauffman Michael
C/O KARYOPHARM THERAPEUTICS INC.
85 WELLS AVENUE
NEWTON
MA
02459
1
1
0
0
Chief Executive Officer
Common Stock
2020-03-10
4
M
0
10000
4.752
A
565122
D
Common Stock
2020-03-10
4
S
0
7932
22.1086
D
557190
D
Common Stock
2020-03-10
4
S
0
2068
22.6405
D
555122
D
Common Stock
2020-03-09
4
M
0
10000
4.752
A
766489
I
By Spouse
Common Stock
2020-03-09
4
S
0
7000
22.5791
D
759489
I
By Spouse
Common Stock
2020-03-09
4
S
0
3000
22.3803
D
756489
I
By Spouse
Stock Option (right to buy)
4.752
2020-03-10
4
M
0
10000
0.00
D
2023-09-02
Common Stock
10000
366061
D
Stock Option (right to buy)
4.752
2020-03-09
4
M
0
10000
0.00
D
2023-09-02
Common Stock
10000
410303
I
By Spouse
These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.57 to $22.55, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.575 to $22.76, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person.
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.095 to $23.04, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.05 to $23.75, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter.
/s/Christopher B. Primiano, Attorney-in-Fact for Michael Kauffman
2020-03-11